As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...

(NASDAQ:BLUE – Get Free Report) had its target price dropped by analysts at Wells Fargo & Company from $40.00 to $5.00 in a ...

The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...

The expansion of the advanced therapy medicinal products market is primarily fueled by the increasing incidence of chronic diseases. The rising prevalence of genetic disorders and cancer, along ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed ...

The main speaker for the event is Aonghus Lane of St David's Poultry veterinary practitioners, who will deliver a ...

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

A national biosecurity webinar will be held amid cases of avian influenza H5N1 (commonly known as bird flu) tomorrow by the ...

Fintel reports that on February 24, 2025, JP Morgan upgraded their outlook for bluebird bio (NasdaqGS:BLUE) from Underweight ...

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...